Covid-19 roundup: FDA authorizes Pfizer/BioNTech vaccine for 12- to 15-year-olds; Novavax shares sink as company delays vaccine timeline

Nicole DeFeudis

Editor

Back-to-school season could look much different this year, as Pfizer and BioNTech’s Covid-19 vaccine has become the first in the US to be authorized for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: FDA authorizes Pfizer/BioNTech vaccine for 12- to 15-year-olds; Novavax shares sink as company delays vaccine timeline

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Covid-19 roundup: FDA au­tho­rizes Pfiz­er/BioN­Tech vac­cine for 12- to 15-year-olds; No­vavax shares sink as com­pa­ny de­lays vac­cine time­line

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Covid-19 roundup: FDA authorizes Pfizer/BioNTech vaccine for 12- to 15-year-olds; Novavax shares sink as company delays vaccine timeline